Introduction 10/27/10 ROLE OF NOVEL BIOMARKERS IN DISEASE PREVENTION: CRP, CT CALCIUM, AND CYSTATIN C

Size: px
Start display at page:

Download "Introduction 10/27/10 ROLE OF NOVEL BIOMARKERS IN DISEASE PREVENTION: CRP, CT CALCIUM, AND CYSTATIN C"

Transcription

1 ROLE OF NOVEL BIOMARKERS IN DISEASE PREVENTION: CRP, CT CALCIUM, AND CYSTATIN C Michael G. Shlipak, MD, MPH Professor of Medicine, University of California, San Francisco Chief, Division of General Internal Medicine, San Francisco VA Medical Center October 27 th, 2010 Introduction Biomarker- new term to represent a measureable biological process Biomarkers most often are blood tests, but can be from DNA, imaging, ECGs, etc. Biomarkers have major scientific roles other than clinical practice. Many primarily used in epidemiology to understand etiology of disease onset and progression Hlatky, Circulation 2009 Useful diagnostic tests- change our clinical management by: Distinguishing the presence/absence or severity of disease Changing our perception of disease risk, with clinical implications Modifiable Risk Factors- information is useful, as provides targets for intervention to reduce disease risk 1

2 Non-Modifiable Risk Factors- information changes individual s likelihood of disease, but does not provide specific target for therapy. Value of prognostic biomarkers is controversialmany new tests have unclear action plans Question 1: Which of the following best describes your attitude toward new diagnostic tests? 1. I am usually excited to use new tests to detect disease or disease risk. 2. I actively learn about new tests because my patients or peers expect me to be knowledgeable. 3. I generally don t like learning about new tests because they rarely improve clinical care. 4. If a test was not part of my clinical training, then I probably won t order it. Outline Update on Key Biomarkers: C-Reactive Protein (CRP) Coronary calcification by CT and other subclinical CVD measures Cystatin C 2

3 Question 2: My practice regarding CRP is best described as: 1. I measure CRP routinely to help with CVD risk stratification. 2. I measure CRP occasionally for challenging decisions for CVD prevention. 3. CRP is often measured as part of a lipid panel, but I rarely use the information. 4. I never think about CRP. C-Reactive Protein (CRP) Blood test that captures systemic inflammation Probably not in disease pathway; triggered by IL-6 CRP is very stable and easy to measure in blood Measuring inflammation has never been standard screening test CRP as a Risk Factor Emerging Risk Factors Collaboration Meta- Analysis: 38 studies 160,309 individuals 1.31 M person-years 27,769 outcomes Koptoge S et al. Lancet,

4 CRP and Heart Disease Risk Koptoge S et al. Lancet 2009 RR for 3-fold higher CRP-Mortality Koptoge S et al. Lancet 2009 Is the CRP-CVD Association Strong Enough? Although CRP is an independent risk factor, it does not add much beyond Framingham Risk Equation Explained partly by CRP s correlation with other cardiovascular risk factors CRP s relative risks only about 2-fold; to improve Framingham Risk Estimates, new risk factor needs RR 3.5 Lloyd-Jones DM et al., Ann Intern Med

5 CRP for Risk Classification CVD risk is classified as: Low Medium High < > 20 risk equivalent risk factors 2 risk factors Can CRP help classify correctly? Some have advocated CRP testing to help separate persons with medium risk Ridker PM et al., NEJM 2002 and Ann Intern Med 2009 Adding CRP to Framingham Risk Assessment in Women 30 Multivariate Relative Risk for CVD CRP Level < 1.0 mg/l CRP Level mg/l CRP Level >3.0 mg/l 0%-1% 2%-4% 5%-9% 10% Lloyd-Jones DM et al., Ann Intern Med 2006 Should CRP Levels be Used to Identify Statin Candidates? JUPITER Trial Design: 17,802 adults without CAD Rosuvastatin 20mg vs placebo Inclusion criteria: LDL < 130 (average 108) CRP > 2 (average 4.2) Outcomes: CVD, death 5

6 JUPITER Rosuvastatin Decreases CVD Risk Ridker PM et al., NEJM 2008 Key Points on JUPITER Statin trial, not a CRP study Demonstrated that statins are beneficial even in low-risk adults with normal LDL Statins likely also beneficial for persons with CRP < 2.0 Therefore, no clear justification to measure CRP USPTS Summary on CRP CRP- the most rigorously studied of novel CVD biomarkers CRP may classify some medium risk persons as high risk, but unclear: the yield of CRP testing why not aggressively treat all med. risk? Current evidence does not support the routine use of CRP for risk stratification Helfand M et al., Ann Intern Med

7 Outline Update on Key Biomarkers: C-Reactive Protein (CRP) Coronary calcification by CT and other subclinical CVD measures Cystatin C Question 3: The use of CT scans for CAD should be used: 1. As an alternative to coronary angiography (cath) for low risk patients. 2. To identify patients with CAD. 3. To decide who to give statins to. 4. There are no compelling indications to measure CT calcification. Coronary Calcification: Introduction CT scans have ability to detect calcium deposits in coronary (and other) arteries Presence of calcification is an indication of atherosclerotic plaque Therefore, detectable calcification in coronary arteries is an indicator of subclinical cardiovascular disease 7

8 Subclinical Cardiovascular Disease Defined as procedures (often radiological imaging) that detect early cardiovascular disease before clinically apparent Not developed as screening tests, but rather to study the development of CVD processes The Role of Subclinical CVD Measures Used to isolate risk factors, such as diabetes, for specific pathological processes that lead to CVD Often used as clinical trial outcomes for Phase 2 studies All valid subclinical CVD measures are associated with clinical CVD events. Current Subclinical CVD Measures Coronary artery calcification (CT)- MI risk Left ventricular hypertrophy (echo, MRI)- heart failure Carotid wall thickness (IMT by u/s)- stroke Ankle brachial index (SBP ratio)-peripheral arterial disease Vascular Stiffness (pulse wave velocity)- central hypertension Processes overlap, so most subclinical CVD measures predict multiple CVD outcomes 8

9 CT Coronary Artery Calcification Score and CAD Events- the MESA Study Detrano R et al., NEJM 2008 CAC Score and CAD Events by Race Detrano R et al., NEJM 2008 The Pros and Cons of CT Screening (or other testing for subclinical CVD) Pros: Stronger risk associations than CRP or other blood tests Specific for the presence of atherosclerosis Could potentially be useful for medium risk individuals needing motivation (e.g. my brother-in-law) ABI is inexpensive, relatively 9

10 The Pros and Cons of CT Screening (or other testing for subclinical CVD) Cons: In older populations and those with diabetes or kidney disease- nearly universal Not reproducible enough for repeat testing Not directly modifiable Radiation exposure $$$ Conclusion on CT-Calcium Score (or other testing for subclinical CVD) USPTF: current evidence does not support routine use of CT Also, does not recommend routine use of ankle brachial index or carotid wall thickness Helfand M et al., Ann Intern Med 2009 My opinion: if patient brings you a report documenting coronary calcification (or LVH, ABI < 0.9), then consider them high risk Outline Update on Key Biomarkers: C-Reactive Protein (CRP) Coronary calcification by CT and other subclinical CVD measures Cystatin C 10

11 Question 4: Regarding cystatin C 1. I first heard of it when I read the syllabus. 2. I saw paper(s) about it but have not read them. 3. I know it s a kidney test, but I don t use it. 4. I have measured cystatin C. What is Cystatin C? Cystatin C is a blood test of kidney function. FDA approved as an alternate measure of kidney function. Marketed by several companies, and is rapidly becoming commercially available. Filtration Marker Principles Creatinine and cystatin C are filtration markers Filtration marker-refers to something measurable in the blood that gives indirect information about the glomerular filtration rate (GFR) Production and elimination Factors affecting creatinine production: Muscle, activity, diet, health status Factors we use to estimate creatinine production Age, sex, race, weight 11

12 Properties of Cystatin C Cystatin C produced in all nucleated cells Constant release into blood, perhaps via cell turnover Freely filtered at glomerulus No renal tubular secretion Cystatin C association with GFR relatively independent of age, sex, race and muscle mass How can we compare tests of Kidney Function? GFR the virtual Gold Standard Measured by clearance of injected tracer Rarely clinically available Never available for population based cohort studies Our strategy- use clinical outcomes associated with kidney disease If cystatin C is better predictor of death or CVD, then probably a better marker of kidney function Comparison with Measured GFR 20 years of studies show cystatin C has closer approximation to measured GFR than creatinine DharnidharkaVR et al. AJKD 2002 Nearly all studies were in patients with kidney disease No GFR studies in the general population 12

13 Cardiovascular Health Study (CHS) Design: NIH sponsored cohort Subjects: Population based elderly cohort from 4 US communities N = 4,444 Mean age: 75 years Cystatin C measured at (Yr 3) visit Mean follow up: 9 years Outcomes: - All cause mortality - Cardiovascular mortality - Heart failure Creatinine Quintiles and Mortality Risk Mortality rate per year (%) Significant adjusted hazard ratio egfr<60 Creatinine 1st 2nd 3rd 4th 5th Quintiles Shlipak MG et al. N Engl J Med 2005 Cystatin C Quintiles and Mortality Risk Mortality rate per year (%) Significant adjusted hazard ratio 1st 2nd 3rd 4th 5th Quintiles Creatinine Cystatin-C Shlipak MG et al. N Engl J Med

14 Creatinine and Cardiovascular Mortality 5 4 Significant adjusted hazard ratio Mortality rate per year (%) 3 2 Creatinine 1 0 1st 2nd 3rd 4th 5th Quintiles Shlipak MG et al. N Engl J Med 2005 Cystatin C and Cardiovascular Mortality 5 Significant adjusted hazard ratio 4 Mortality rate per year (%) Creatinine Cystatin-C 0 1st 2nd 3rd 4th 5th Quintiles Shlipak MG et al. N Engl J Med 2005 Kidney Function and Heart Failure Incidence Incidence Rates per Year(%) Significant adjusted hazard ratio Cystatin C egfr Quintiles Sarnak MJ et al. Ann Intern Med

15 Confirmation Studies Cohort/Study Population Outcome(s) Health ABC Shlipak et al., JASN 2006 Bibbins-Domingo, Arch Intern Med 2006 Heart and Soul Ix, Circulation 2007 NHANES III Astor, JASN 2009 MDRD Study Menon, Arch Intern Med 2007 Elderly CAD General population Advanced CKD Death, heart failure Recurrent CVD Death Death What Clinical Need could Cystatin C Fill? Predicting risk- probably inadequate to justify ordering a new test (see CRP) However, 10s of millions of creatinine tests ordered each year Potential roles for cystatin C: Better classification of CKD Identifying preclinical impairment of kidney function Targeting specific populations with unpredictable muscle mass Pre-op risk stratification before surgery or contrast CKD Definition by Creatinine and Cystatin C In early work, we considered creatinine insensitive, but specific. However, from the nephrologist standpoint, specificity is a problem. Among 16 million in the U.S. with egfrcreat <60, who has real CKD? We compared prognostic value of CKD defined by creatinine and/or cystatin C Peralta CA et al., J Am Soc Nephrol, in press

16 CKD Definitions in the Elderly Cardiovascular Health Study- mean age 72 Rate (1000 person years) Rate of Mortality in CHS N=73% N=6% N=9% N=12% Neither Cystatin C Creatinine Both No CKD: 8% with missed CKD CKD definition CKD: 57% with real CKD CHS: CKD and Mortality All Cause Mortality Multivariate Adjusted Hazard Ratios with 95% Confidence Intervals 3345 deaths No Decreased egfr 1.00 (ref) Decreased egfrcr only 1.09 (0.98, 1.21) Decreased egfrcys only 1.78 (1.53, 2.08) Decreased egfr both 1.74 (1.58, 1.93) CHS: CKD and Cardiovascular Disease Cardiovascular Disease Multivariate Adjusted Hazard Ratios with 95% Confidence Intervals 2249 events No Decreased egfr 1.00 (ref) Decreased egfrcr only 1.05 (0.92, 1.20) Decreased egfrcys only 1.52 (1.26, 1.84) Decreased egfr both 1.46 (1.29, 1.65) 16

17 CHS: CKD and Heart Failure Heart Failure Multivariate Adjusted Hazard Ratios with 95% Confidence Intervals 1407 events No Decreased egfr 1.00 (ref) Decreased egfrcr only 0.99 (0.84, 1.18) Decreased egfrcys only 1.69 (1.33, 2.13) Decreased egfr both 1.43 (1.22, 1.67) CHS: CKD and ESRD Kidney Failure Multivariate Adjusted Hazard Ratios with 95% Confidence Intervals 84 events No Decreased egfr 1.00 (ref) Decreased egfrcr only 2.60 (1.00, 6.75) Decreased egfrcys only 6.14 (2.18, 17.29) Decreased egfr both (12.68, 44.76) CKD Definitions in the Middle-Aged Multi-Ethnic Study of Atherosclerosis- mean age ~60 Rate of Mortality in MESA CKD: 30% with real CKD Rate (1000 person years) N=88% N=2% N=7% N=3% Neither Cystatin C Creatinine Both No CKD: 2% with missed CKD CKD definition 17

18 Summary on CKD Classification A large proportion of CKD defined by creatinine are either false positives or low risk CKD. Cystatin C distinguishes the high risk CKD and identifies additional CKD missed by creatinine Practical Issues for Cystatin C Upcoming CKD Guidelines will discuss the clinical role of cystatin C Currently, limited availability of cystatin C because earlier method requires special machine At UCSF, has been available as a send out test New cystatin C assays -can be run on nearly all clinical chemistry analyzes. Costs: Medicare reimbursement: $19 Assay costs: $6/test Lab charges: variable Thank You Questions? 18

Outline. Outline CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW. Question 1: Which of these patients has CKD?

Outline. Outline CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW. Question 1: Which of these patients has CKD? CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,

More information

Outline. Outline NEW DEVELOPMENTS IN MANAGEMENT OF CHRONIC KIDNEY DISEASE. Question 1: Which of these patients has chronic kidney disease?

Outline. Outline NEW DEVELOPMENTS IN MANAGEMENT OF CHRONIC KIDNEY DISEASE. Question 1: Which of these patients has chronic kidney disease? NEW DEVELOPMENTS IN MANAGEMENT OF CHRONIC KIDNEY DISEASE MICHAEL G. SHLIPAK, MD, MPH PROFESSOR OF MEDICINE, UCSF CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER August 13, 2010 Question

More information

10/25/2013. November 5 th, 2013

10/25/2013. November 5 th, 2013 Michael G. Shlipak, MD, MPH Professor of Medicine, Epidemiology and Biostatistics, UCSF Chief, General Internal Medicine, San Francisco VA Medical Center November 5 th, 2013 Early onset of kidney disease

More information

What do I do with CRP? Michael Blazing MD Associate Professor DUMC/DCRI

What do I do with CRP? Michael Blazing MD Associate Professor DUMC/DCRI What do I do with CRP? Michael Blazing MD Associate Professor DUMC/DCRI Disclosures Honoraria MSD Consultant Research Pfizer, Merck, Merck, CSL S-P/Merck, CSL Overview hscrp What is it? What is it not

More information

Assessing Cardiovascular Risk. Why Assess CVD Risk? Intensity of Treatment Should Match the CVD Risk.

Assessing Cardiovascular Risk. Why Assess CVD Risk? Intensity of Treatment Should Match the CVD Risk. Assessing Cardiovascular Risk Peter Ganz, MD Chief, Division of Cardiology Director, Center of Excellence in Vascular Research San Francisco General Hospital Maurice Eliaser Distinguished Professor of

More information

Disclosures. Outline. Outline CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW 8/12/2016

Disclosures. Outline. Outline CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW 8/12/2016 CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,

More information

SLIDES ARE POSTED NEW GUIDELINES FOR TREATMENT OF CHOLESTEROL: IMPLICATIONS FOR THE PREVENTION OF HEART DISEASE AND STROKE

SLIDES ARE POSTED NEW GUIDELINES FOR TREATMENT OF CHOLESTEROL: IMPLICATIONS FOR THE PREVENTION OF HEART DISEASE AND STROKE NEW GUIDELINES FOR TREATMENT OF CHOLESTEROL: IMPLICATIONS FOR THE PREVENTION OF HEART DISEASE AND STROKE Robert B. Baron MD MS I have no relevant conflicts of interest Professor of Medicine Associate Dean

More information

Coronary artery calcium scoring. Con Aroney AM MD, FRACP, FCSANZ Queensland Cardiology

Coronary artery calcium scoring. Con Aroney AM MD, FRACP, FCSANZ Queensland Cardiology Coronary artery calcium scoring Con Aroney AM MD, FRACP, FCSANZ Queensland Cardiology Predicting cardiac events in asymptomatic people Risk Factors Hypertension Smoking Dyslipidemia Family History Diabetes/

More information

Objectives. Who faces a higher mortality from cardiovascular related illness? Epidemiology of CVD. Cardiovascular Disease Management in Women

Objectives. Who faces a higher mortality from cardiovascular related illness? Epidemiology of CVD. Cardiovascular Disease Management in Women Cardiovascular Disease Management in Objectives. Epidemiology 2. Risk Stratification 3. Depression Screening in 4. Aspirin Use in 5. Summary Lisa Ward, MD, MSPH, MS Associate Clinical Professor Santa Rosa

More information

Overview of Acute Kidney Injury and Chronic Kidney Disease

Overview of Acute Kidney Injury and Chronic Kidney Disease Overview of Acute Kidney Injury and Chronic Kidney Disease Ali K. Abu-Alfa, MD, FASN Professor of Medicine Head, Division of Nephrology & Hypertension Director, Human Research Protection Program and the

More information

Prevention of Cardiovascular Disease in Children with Diabetes

Prevention of Cardiovascular Disease in Children with Diabetes Prevention of Cardiovascular Disease in Children with Diabetes Stephen R. Daniels, MD, PhD Department of Pediatrics University of Colorado School of Medicine The Children s Hospital Anschutz Medical Campus

More information

10 Year CVD Risk. Peter W. F. Wilson, M.D. Emory University, Atlanta, GA

10 Year CVD Risk. Peter W. F. Wilson, M.D. Emory University, Atlanta, GA 10 Year CVD Risk Peter W. F. Wilson, M.D. Emory University, Atlanta, GA Disclosures Grants: Merck Consultant: Merck Janssen XZK Glaxo-Smith-Kline Astra-Zeneca Risk Prediction Key Issues Risk Factors Specimen

More information

Costing statement: Chronic kidney disease Implementing the NICE guideline on chronic kidney disease (CG182)

Costing statement: Chronic kidney disease Implementing the NICE guideline on chronic kidney disease (CG182) Putting NICE guidance into practice Costing statement: Chronic kidney disease Implementing the NICE guideline on chronic kidney disease (CG182) Published: July 2014 1 Introduction 1.1 This costing statement

More information

Justification for Chronic Kidney Disease Subgroup in SPRINT

Justification for Chronic Kidney Disease Subgroup in SPRINT Justification for Chronic Kidney Disease Subgroup in SPRINT American Society of Hypertension 27 th Annual Meeting, May 20, 2012 Alfred K. Cheung, M.D. University of Utah American Society of Hypertension,

More information

JNC 8 HYPERTENSION GUIDELINES AND

JNC 8 HYPERTENSION GUIDELINES AND JNC 8 HYPERTENSION GUIDELINES AND THE BLOOD PRESSURE LIMBO H OW LOW SHOULD YOU GO? LOW H IGH 32nd Annual Advances in Heart Disease December 18, 2015 Binh An P. Phan, MD Associate Professor of Medicine

More information

Lipid Management in CKD: Insights from the SHARP Trial

Lipid Management in CKD: Insights from the SHARP Trial 1 Lipid Management in CKD: Insights from the SHARP Trial George Bakris, MD, FAHA, FASN Professor of Medicine Director, Hypertensive Diseases Center The University of Chicago-Pritzker School of Medicine

More information

Estimated GFR Based on Creatinine and Cystatin C

Estimated GFR Based on Creatinine and Cystatin C Estimated GFR Based on Creatinine and Cystatin C Lesley A Stevens, MD, MS Tufts Medical Center, Tufts University School of Medicine Boston MA Chronic Kidney Disease-Epidemiology Collaboration UO1 DK 053869,

More information

The effect of chronic diseases on cognitive aging

The effect of chronic diseases on cognitive aging Projected Prevalence of Alzheimer Disease in the U.S. The effect of chronic diseases on cognitive aging Kristine Yaffe, MD Univ. of California, San Francisco San Francisco VA Medical Center U.S. Prevalence

More information

In predicting CKD risk, egfr better when based on cystatin C

In predicting CKD risk, egfr better when based on cystatin C In predicting CKD risk, egfr better when based on cystatin C Anne Paxton Like turning around an ocean-going tanker, changing widely accepted testing practices in kidney disease, one of the nation s most

More information

MANAGEMENT OF LIPID DISORDERS: IMPLICATIONS OF THE NEW GUIDELINES

MANAGEMENT OF LIPID DISORDERS: IMPLICATIONS OF THE NEW GUIDELINES MANAGEMENT OF LIPID DISORDERS: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING

More information

SPRINT: A RANDOMIZED TRIAL OF INTENSIVE VERSUS STANDARD BLOOD-PRESSURE CONTROL

SPRINT: A RANDOMIZED TRIAL OF INTENSIVE VERSUS STANDARD BLOOD-PRESSURE CONTROL 1 SPRINT: A RANDOMIZED TRIAL OF INTENSIVE VERSUS STANDARD BLOOD-PRESSURE CONTROL Presenter: Mackenzie Clark, PharmD, BCPS University of California, San Francisco Medical Center 2 Disclosures I have no

More information

Listen to your heart: Good Cardiovascular Health for Life

Listen to your heart: Good Cardiovascular Health for Life Listen to your heart: Good Cardiovascular Health for Life Luis R. Castellanos MD, MPH Assistant Clinical Professor of Medicine University of California San Diego School of Medicine Sulpizio Family Cardiovascular

More information

Medical Management of Carotid Stenosis

Medical Management of Carotid Stenosis Medical Management of Carotid Stenosis Thomas F. Rehring, MD, FACS Disclosures: None Regional Department Chief Department of Vascular Therapy Colorado Permanente Medical Group Clinical Associate Professor

More information

Identifying Chronic Kidney Disease (CKD) Advantages and Pitfalls of the Current Classification System. Risk Factors. Costs of CKD.

Identifying Chronic Kidney Disease (CKD) Advantages and Pitfalls of the Current Classification System. Risk Factors. Costs of CKD. Identifying Chronic Kidney Disease (CKD) Advantages and Pitfalls of the Current Classification System Risk Factors Costs of CKD End of Life Mark D. Purcell DO Nephrology/Internal Medicine Carolina Nephrology,

More information

Cardiovascular Disease Prevention. Dr Nicole KARAM, MD, MPH Interventional Cardiology European Hospital Georges Pompidou

Cardiovascular Disease Prevention. Dr Nicole KARAM, MD, MPH Interventional Cardiology European Hospital Georges Pompidou Cardiovascular Disease Prevention Dr Nicole KARAM, MD, MPH Interventional Cardiology European Hospital Georges Pompidou Atherosclerotic CVD, especially CHD, remains the leading cause of premature death

More information

New Cholesterol Guidelines: Carte Blanche for Statin Overuse Rita F. Redberg, MD, MSc Professor of Medicine

New Cholesterol Guidelines: Carte Blanche for Statin Overuse Rita F. Redberg, MD, MSc Professor of Medicine New Cholesterol Guidelines: Carte Blanche for Statin Overuse Rita F. Redberg, MD, MSc Professor of Medicine Disclosures & Relevant Relationships I have nothing to disclose No financial conflicts Editor,

More information

Controversy, the JNC-8 Hypertension Guidelines

Controversy, the JNC-8 Hypertension Guidelines Controversy, the JNC-8 Hypertension Guidelines Christopher J. Cooper, M.D., FACC, FACP Dean and Senior Vice President University of Toledo, College of Medicine Acknowledge assistance of Kevin Kun Xiang,

More information

Nephelometric assays- Urine 24 collection and kidney function test

Nephelometric assays- Urine 24 collection and kidney function test Nephelometric assays- Urine 24 collection and kidney function test Hamad Ali Yaseen, PhD MLS Department, FAHS, HSC Hamad.ali@hsc.edu.kw Clinical Chemistry II (467) Urinary System Kidneys remove excess

More information

Chronic kidney disease and cerebral small vessel disease

Chronic kidney disease and cerebral small vessel disease Chronic kidney disease and cerebral small vessel disease M. Arfan Ikram, MD PhD Department of Epidemiology, Radiology, Neurology Erasmus MC Rotterdam, The Netherlands No disclosures Kidney-brain: Two pulsating

More information

Chronic Kidney Disease: Proposed Revisions to the ICD-9-CM Classification

Chronic Kidney Disease: Proposed Revisions to the ICD-9-CM Classification Chronic Kidney Disease: Proposed Revisions to the ICD-9-CM Classification Lesley Stevens MD Tufts-New England Medical Center National Kidney Foundation Objectives Kidney Failure Stages of Chronic Kidney

More information

PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN

PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING THE DECREASE

More information

Diabetic Nephropathy. Andreas Jehle Transplantation Immunology & Nephrology, University Hospital, Basel

Diabetic Nephropathy. Andreas Jehle Transplantation Immunology & Nephrology, University Hospital, Basel Diabetic Nephropathy Andreas Jehle Transplantation Immunology & Nephrology, University Hospital, Basel Prevalence of ESRD According to Diagnosis (USA) Obesity, D.m. Expectancy of Live USRDS 2013 Incidence

More information

Diagnostik. Michael Rudnicki. Medizinische Universität t Innsbruck Univ. Klinik für f r Innere Medizin IV Nephrologie und Hypertensiologie 16.3.

Diagnostik. Michael Rudnicki. Medizinische Universität t Innsbruck Univ. Klinik für f r Innere Medizin IV Nephrologie und Hypertensiologie 16.3. Diagnostik Michael Rudnicki Medizinische Universität t Innsbruck Univ. Klinik für f r Innere Medizin IV Nephrologie und Hypertensiologie ÖGN Wintermeeting, Fuschl,, 14.-16.3.2013 16.3.2013 Kidney International

More information

Kidney Care for Primary Care: Trying to Keep it Simple. Dr. John Pawlovich, FCFP November 30, 2013 Family Physician Forum, Vancouver, BC

Kidney Care for Primary Care: Trying to Keep it Simple. Dr. John Pawlovich, FCFP November 30, 2013 Family Physician Forum, Vancouver, BC Kidney Care for Primary Care: Trying to Keep it Simple Dr. John Pawlovich, FCFP November 30, 2013 Family Physician Forum, Vancouver, BC None Disclosures Objectives Review the role of Primary Care Review

More information

Ραδιοϊσοτοπική εκτίμηση της νεφρικής λειτουργίας

Ραδιοϊσοτοπική εκτίμηση της νεφρικής λειτουργίας Σακχαρώδης Διαβήτης & χρόνια νεφρική νόσος Ραδιοϊσοτοπική εκτίμηση της νεφρικής λειτουργίας Γ. Αρσος ΓΝΘ Ιπποκράτειο GFR : Glomerular filtration rate GFR is widely accepted as the best index of kidney

More information

Women and Coronary Artery Disease Where Are We Now? Shani S. Saks, DO, MS October 16, 2009

Women and Coronary Artery Disease Where Are We Now? Shani S. Saks, DO, MS October 16, 2009 Women and Coronary Artery Disease Where Are We Now? Shani S. Saks, DO, MS October 16, 2009 Historical Perspective Another point to remember is that angina pectoris is, like gout, a disease of men, and

More information

Treatment of Hypertension in Patients on Hemodialysis. Hermann Haller Department of Nephrology Hannover Medical School

Treatment of Hypertension in Patients on Hemodialysis. Hermann Haller Department of Nephrology Hannover Medical School Treatment of Hypertension in Patients on Hemodialysis Hermann Haller Department of Nephrology Hannover Medical School Blood pressure treatment - conventional wisdom in ESRD patients Salt??? Changes over

More information

Suggestions for Laboratories

Suggestions for Laboratories Suggestions for Laboratories This document has been developed by the National Kidney Disease Education Program (NKDEP) to provide clinical laboratories with information that can help them: accurately report

More information

CT, MR and Renal function in a GFR world

CT, MR and Renal function in a GFR world Objectives: CT, MR and Renal function in a GFR world 1. Review the NKF definition of chronic renal disease 2. Review risk factors for CIN and NSF 3. Provide a framework for using egfr to manage patients

More information

CLEAN. What Do Your Arteries Look Like - Clean or Clogged? Thick or Thin? What Do Your Arteries Look Like - Clean or Clogged? Thick or Thin?

CLEAN. What Do Your Arteries Look Like - Clean or Clogged? Thick or Thin? What Do Your Arteries Look Like - Clean or Clogged? Thick or Thin? ASK YOUR DOCTOR ABOUT What Do Your Arteries Look Like - Clean or Clogged? Thick or Thin? CLEAN Visit www.cardiohealthtest.com an affiliated company of Panasonic Healthcare Co., Ltd. CardioHealth is a registered

More information

Prevalence and Correlates Of High Normal Blood Pressure

Prevalence and Correlates Of High Normal Blood Pressure Slide ١ Prevalence and Correlates Of High Normal Blood Pressure MAGDY ABDEL HAMID, MD Associate Professor of Cardiology Cairo University Slide ٢ Slide ٣ Prevalence of High Normal BP In the US, 13 % of

More information

Background. Stages. we detect these easily? New technology: The CT scanner, 1971. Example: calcium in peripheral vascular disease.

Background. Stages. we detect these easily? New technology: The CT scanner, 1971. Example: calcium in peripheral vascular disease. Coronary Calcium Background Ahtherosclerosis: Maturation of a plaque into symptomatic disease Coronary Artery disease Fatty Streak: Autopsy, seen in autopsy Occurs very early, 0s, late teens Seen almost

More information

Coronary Calcium Scoring: the Logical Way to Assess CVS Risk?

Coronary Calcium Scoring: the Logical Way to Assess CVS Risk? Coronary Calcium Scoring: the Logical Way to Assess CVS Risk? Dr Chris Ellis Cardiologist Greenlane CVS Service Auckland City Hospital & Auckland Heart Group AHG Winter Symposium. 24 July 2010 (Is) Coronary

More information

Learning Objectives Patient Care: Prevention/General Cardiology

Learning Objectives Patient Care: Prevention/General Cardiology Rotation: Director: Faculty: Preventive /General Cardiology Emily G. Kurtz, M.D./Waleed Irani, M.D. Prevention: Jeff Boord, M.D., Sergio Fazio, M.D., Emily G. Kurtz, M.D., MacRae Linton, M.D., David Maron,

More information

Surrogate Endpoints in CV Research: Regulatory implications for the use of surrogate endpoints

Surrogate Endpoints in CV Research: Regulatory implications for the use of surrogate endpoints Surrogate Endpoints in CV Research: Regulatory implications for the use of surrogate endpoints Pieter de Graeff Medicines Evaluation Board The Netherlands 1 Definitions of endpoints (NIH) Biomarkers #

More information

Chronic Kidney disease following Acute Kidney Injury. Tushar Vachharajani, MD VAMC Salisbury, NC

Chronic Kidney disease following Acute Kidney Injury. Tushar Vachharajani, MD VAMC Salisbury, NC K D IG O Chronic Kidney disease following Acute Kidney Injury Tushar Vachharajani, MD VAMC Salisbury, NC Traditional concept of AKI recovery 1 Pre-renal phase 2 Initiation 3 Extension 4 Maintenance 5 Recovery

More information

ASCVD Risk Calculators, Controversies and Women

ASCVD Risk Calculators, Controversies and Women ASCVD Risk Calculators, Controversies and Women Ann Cannon, RN, BSN Clinical Specialist for Cardiovascular Health and Heart Failure, MaineHealth Nurse Care Manager, Turning Point Heart Health Program Maine

More information

Renal disease in Canada Understanding the Challenge

Renal disease in Canada Understanding the Challenge Renal disease in Canada Understanding the Challenge CKD Symposium November 30, 2013 Monica Beaulieu, MD FRCPC MHA NEPHROLOGY/INTERNAL MEDICINE THE UNIVERSITY OF BRITISH COLUMBIA BRITISH COLUMBIA RENAL

More information

CHRONIC KIDNEY DISEASE PRACTICE GUIDELINES

CHRONIC KIDNEY DISEASE PRACTICE GUIDELINES CHRONIC KIDNEY DISEASE PRACTICE GUIDELINES Reviewed and approved 5/2014 Risk Chronic kidney disease is defined as either kidney damage or decreased kidney function (decreased GFR) for 3 or more months.

More information

Computed tomography coronary angiography in patients with suspected coronary artery disease

Computed tomography coronary angiography in patients with suspected coronary artery disease Computed tomography coronary angiography in patients with suspected coronary artery disease Prof. Dr. Stephen Schröder, EC, FESC Department of Cardiology Klinik am Eichert Göppingen Germany -No conflicts

More information

ASSESSMENT OF CARDIOVASCULAR RISK

ASSESSMENT OF CARDIOVASCULAR RISK ASSESSMENT OF CARDIOVASCULAR RISK M MOHSEN IBRAHIM, MD CARDIOLOGY DEPARTMENT-CAIRO UNIVERSITY The Complications of CAD Often Emerge without Warning Adapted from Levy et al, Textbook of Cardiovascular Medicine,

More information

Chapter 1: CKD in the General Population

Chapter 1: CKD in the General Population Chapter 1: CKD in the General Population Introduction In this chapter we provide single-sample, crosssectional estimates of kidney function through data downloaded in 2014 from the National Health and

More information

Main Effect of Screening for Coronary Artery Disease Using CT

Main Effect of Screening for Coronary Artery Disease Using CT Main Effect of Screening for Coronary Artery Disease Using CT Angiography on Mortality and Cardiac Events in High risk Patients with Diabetes: The FACTOR-64 Randomized Clinical Trial Joseph B. Muhlestein,

More information

IS A LOWER BP BETTER IN DKD? KDIGO. George L. Bakris, MD, F.A.S.N. Professor of Medicine University of Chicago Medicine

IS A LOWER BP BETTER IN DKD? KDIGO. George L. Bakris, MD, F.A.S.N. Professor of Medicine University of Chicago Medicine IS A LOWER BP BETTER IN DKD? George L. Bakris, MD, F.A.S.N. Professor of Medicine University of Chicago Medicine Disclosure of Interests Investigator Initiated Grant/Research Support- TAKEDA (direct funding

More information

Abstract. Gowtham Kishore A 1, P. Seenivasan 1, M. Edwin Fernando 2 INTRODUCTION OBJECTIVES. Stanley Medical Journal

Abstract. Gowtham Kishore A 1, P. Seenivasan 1, M. Edwin Fernando 2 INTRODUCTION OBJECTIVES. Stanley Medical Journal A COMPARATIVE STUDY ON GLOMERULAR FILTRATION RATE ESTIMATED FROM SERUM CREATININE BETWEEN COCKCROFT-GAULT AND CKD-EPI EQUATIONS IN THE GENERAL POPULATION Gowtham Kishore A 1, P. Seenivasan 1, M. Edwin

More information

INNOVATIONS IN CLINICAL DIAGNOSTICS

INNOVATIONS IN CLINICAL DIAGNOSTICS CYSTATIN C An Improved Way To Screen For Chronic Kidney Disease DIAZYME INNOVATIONS IN CLINICAL DIAGNOSTICS Our data suggests that estimated GFR based on serum Cystatin C could be used as a confirmatory

More information

New targets and treatments: Understanding LDL P, Non HDL C, and ApoB

New targets and treatments: Understanding LDL P, Non HDL C, and ApoB New targets and treatments: Understanding LDL P, Non HDL C, and ApoB Samia Mora, MD, MHS Associate Physician, BWH Heart and Vascular Center; Assistant Professor of Medicine, Harvard Medical School www.brighamandwomens.org/heart

More information

Primary Prevention of Coronary Artery Disease. Raj Thaman Consultant Cardiologist Wrexham Maelor

Primary Prevention of Coronary Artery Disease. Raj Thaman Consultant Cardiologist Wrexham Maelor Primary Prevention of Coronary Artery Disease Raj Thaman Consultant Cardiologist Wrexham Maelor Objectives Define primary prevention and discuss why primary prevention is necessary. review current approaches

More information

Kidney Disease and Hypertension in Diabetes: Early diagnosis and Aggressive Management are Key

Kidney Disease and Hypertension in Diabetes: Early diagnosis and Aggressive Management are Key Kidney Disease and Hypertension in Diabetes: Early diagnosis and Aggressive Management are Key ROBERT C. STANTON, MD Associate Professor of Medicine Harvard Medical School Chief of Nephrology Joslin Diabetes

More information

Underwriter s Review of Laboratory Data Optimum Re November 2011

Underwriter s Review of Laboratory Data Optimum Re November 2011 Underwriter s Review of Laboratory Data Optimum Re November 2011 Robert L. Stout, Ph.D., Director and President Clinical Reference Laboratory Today s discussion is on. Serum creatinine, blood urea nitrogen

More information

American Association of Clinical Chemistry. Contois JH, et al. Clinical Chemistry 2009; 55:

American Association of Clinical Chemistry. Contois JH, et al. Clinical Chemistry 2009; 55: American Association of Clinical Chemistry Recommendations from AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices LDL particles, not simply LDL-C, play a central role in

More information

Statins and Primary Prevention in the Elderly What the HDL??? Sarah Earle November 21 st, Objectives

Statins and Primary Prevention in the Elderly What the HDL??? Sarah Earle November 21 st, Objectives Statins and Primary Prevention in the Elderly What the HDL??? Sarah Earle November 21 st, 2013 Objectives Screening Are we biased against older adults? Secondary Prevention Primary Prevention Treatment

More information

NON-RENAL OUTCOMES IN RENAL TRIALS KDIGO. Michael Walsh McMaster University

NON-RENAL OUTCOMES IN RENAL TRIALS KDIGO. Michael Walsh McMaster University NON-RENAL OUTCOMES IN RENAL TRIALS Michael Walsh McMaster University Disclosure of Interests Ionis Pharmaceuticals - consultancy Bayer - consultancy Abbott Diagnostics research grant (in-kind) Overview

More information

Chronic Kidney Disease in the Elderly Patient: Less May Be More

Chronic Kidney Disease in the Elderly Patient: Less May Be More Chronic Kidney Disease in the Elderly Patient: Less May Be More Theodore F. Saad, MD Nephrology Associates, PA Chief, Section of Renal & Hypertensive Diseases Christiana Care Health System Newark, Delaware

More information

Systolic Blood Pressure Intervention Trial (SPRINT) Principal Results

Systolic Blood Pressure Intervention Trial (SPRINT) Principal Results Systolic Blood Pressure Intervention Trial (SPRINT) Principal Results Paul K. Whelton, MB, MD, MSc Chair, SPRINT Steering Committee Tulane University School of Public Health and Tropical Medicine, and

More information

Arsenic Research at Low Exposure Levels: Exposure Assessment Challenges and Possible Solutions

Arsenic Research at Low Exposure Levels: Exposure Assessment Challenges and Possible Solutions Arsenic Research at Low Exposure Levels: Exposure Assessment Challenges and Possible Solutions Ana Navas-Acien, MD, PhD Environmental Health Sciences Mailman School of Public Health Columbia University

More information

CKD in the Elderly. Outline

CKD in the Elderly. Outline CKD in the Elderly Diana Jalal, M.D. Associate Professor Clinical Director of Renal at UCH Outline CKD in the elderly: a public health issue? Assessment of renal function in the elderly Management of hypertension

More information

DISCLOSURES RISK ASSESSMENT. Stroke and Heart Disease -Is there a Link Beyond Risk Factors? Daniel Lackland, MD

DISCLOSURES RISK ASSESSMENT. Stroke and Heart Disease -Is there a Link Beyond Risk Factors? Daniel Lackland, MD STROKE AND HEART DISEASE IS THERE A LINK BEYOND RISK FACTORS? D AN IE L T. L AC K L AN D DISCLOSURES Member of NHLBI Risk Assessment Workgroup RISK ASSESSMENT Count major risk factors For patients with

More information

Cholesterol Screening and Treatment in Adults Review of the 2013 AHA/ACC Cholesterol Guidelines (and a bit about kids)

Cholesterol Screening and Treatment in Adults Review of the 2013 AHA/ACC Cholesterol Guidelines (and a bit about kids) Cholesterol Screening and Treatment in Adults Review of the 2013 AHA/ACC Cholesterol Guidelines (and a bit about kids) Brian Waite, MD Keweenaw Medical Conference August 29, 2015 Cholesterol Bad Leading

More information

NEW RISK FACTORS FOR HEART DISEASE

NEW RISK FACTORS FOR HEART DISEASE NEW RISK FACTORS FOR HEART DISEASE January 2005 Peter King, MD, FACP, FACC Director, Hong Kong Heart Centre Adventist Health Hong Kong A GLOBAL SNAPSHOT OF HEART DISEASE Heart disease and stroke no longer

More information

Title: Low serum bicarbonate as a predictor of kidney function decline and incident chronic kidney disease: The Multi-Ethnic Study of Atherosclerosis

Title: Low serum bicarbonate as a predictor of kidney function decline and incident chronic kidney disease: The Multi-Ethnic Study of Atherosclerosis Title: Low serum bicarbonate as a predictor of kidney function decline and incident chronic kidney disease: The Multi-Ethnic Study of Atherosclerosis Type of study: Retrospective cohort study Lead investigator:

More information

Subclinical Hypothyroidism & Metabolic Disease

Subclinical Hypothyroidism & Metabolic Disease Subclinical Hypothyroidism & Metabolic Disease Michael D. Loughner, M.D. Endocrinology Associates, Denver, CO 303-722-4683 (p), 303-778-0726 (fax) May 2010 Subclinical Hypothyroidism (SCH) AKA Mild Thyroid

More information

CCS Dyslipidemia Guidelines Update: Emerging Evidence and 2015 Draft Recommendations Discussion

CCS Dyslipidemia Guidelines Update: Emerging Evidence and 2015 Draft Recommendations Discussion CCS Update: Emerging Evidence and 2015 Draft Recommendations Discussion March 2016 Todd Anderson Libin Cardiovascular Institute Todd Anderson Disclosures Advisory board: Merck Clinical Trials: AMGEN, Merck,

More information

Taking Good Care of Your Heart

Taking Good Care of Your Heart Taking Good Care of Your Heart Preventive Cardiology PREVENTIVE CARDIOLOGY CARE Great strides have been made in heart care. In the case of heart disease and stroke, medical breakthroughs mean that patients

More information

Case Study: LDL and HDL Cholesterol

Case Study: LDL and HDL Cholesterol Case Study: LDL and HDL Cholesterol 1 CHD Risk: HDL-Chol and LDL-Chol as Predictors RR of CHD After 4 Y 3.0 2.0 1.0 0.0 100 160 220 85 LDL-C mg/dl 25 65 45 HDL-C mg/dl Men aged 50 70 y in the Framingham

More information

The New Role of STAT Creatinine Testing Presenter: Brad S. Karon MD, PhD. Sponsored by

The New Role of STAT Creatinine Testing Presenter: Brad S. Karon MD, PhD. Sponsored by The New Role of STAT Creatinine Testing Presenter: Brad S. Karon MD, PhD Sponsored by We will begin shortly. If you need assistance with audio, call 434 202 8365. Brad S. Karon MD, PhD Director, Point

More information

Lipids: Understanding The New Prevention Guidelines

Lipids: Understanding The New Prevention Guidelines Lipids: Understanding The New Prevention Guidelines What you need to know J. Murray Estess MD Don t shoot the Messenger What has changed compared to ATP3 guideline? Initiate either moderate-intensity or

More information

Cholesterol Treatment Targets and Clinical Outcomes A JUPITER Trial Update

Cholesterol Treatment Targets and Clinical Outcomes A JUPITER Trial Update AHA Clinical Trial Updates 2015 November 10, 2015 Cholesterol Treatment Targets and Clinical Outcomes A JUPITER Trial Update Percent Reduction in LDL Cholesterol Following High Intensity Statin Therapy:

More information

Clinical Practice Guideline for Adult Hypertension - Prevention, Screening, Counseling and Management

Clinical Practice Guideline for Adult Hypertension - Prevention, Screening, Counseling and Management Clinical Practice Guideline for Adult - Prevention, Screening, Counseling and Management is the most common primary diagnosis in America. About 78 million US adults have been diagnosed with high blood

More information

Watch for Potential Changes in Canada s Current Hypertension and Dyslipidemia Guidelines

Watch for Potential Changes in Canada s Current Hypertension and Dyslipidemia Guidelines College of Pharmacy and Nutrition University of Saskatchewan Saskatoon SK S7N 5C9 www.medsask.usask.ca Vol. 31, No. 2 April 2014 Watch for Potential Changes in Canada s Current Hypertension and Dyslipidemia

More information

Chronic Kidney Disease and Cardiovascular Risk: Interrelationships and Interventions

Chronic Kidney Disease and Cardiovascular Risk: Interrelationships and Interventions Chronic Kidney Disease and Cardiovascular Risk: Interrelationships and Interventions ROBERT C. STANTON, MD Associate Professor of Medicine Harvard Medical School Chief of Nephrology Joslin Diabetes Center

More information

Hypercholesterolemia Treatment

Hypercholesterolemia Treatment Hypercholesterolemia Treatment Screening As per the National Guideline Clearing House (NGC) and Agency for Healthcare Research and Quality, U.S. Preventive Services Task Force (USPSTF) the recommended

More information

Carotid Artery Screening

Carotid Artery Screening Scan for mobile link. Carotid Artery Screening What is carotid artery screening? Screening examinations are tests performed to find disease before symptoms begin. The goal of screening is to detect disease

More information

Advancements in Blood Pressure Management

Advancements in Blood Pressure Management Advancements in Blood Pressure Management New technology for better management of anti-hypertension medications and improved assessment of cardiovascular risk For over 100 years, physicians have relied

More information

Diagnostic algorithms for CAD assessment Chronic stable angina- When is calcium score and CTA first choice? Prof.Dr. Stephen Schröder, FESC

Diagnostic algorithms for CAD assessment Chronic stable angina- When is calcium score and CTA first choice? Prof.Dr. Stephen Schröder, FESC Diagnostic algorithms for CAD assessment Chronic stable angina- When is calcium score and CTA first choice? Prof.Dr. Stephen Schröder, FESC Klinik für Kardiologie, Pneumologie und Angiologie mit Lokaler

More information

The Wait is Over: Updated Guidelines for Cholesterol, Diabetes, and Blood Pressure

The Wait is Over: Updated Guidelines for Cholesterol, Diabetes, and Blood Pressure The Wait is Over: Updated Guidelines for Cholesterol, Diabetes, and Blood Pressure Kisha O Neal Gant, BS, PharmD, BCACP, CGP Clinical Assistant Professor Xavier University of Louisiana Louisiana Pharmacists

More information

COMMITTEE FOR HUMAN MEDICINAL PRODUCTS (CHMP) DRAFT GUIDELINE ON THE EVALUATION OF MEDICINAL PRODUCTS FOR CARDIOVASCULAR DISEASE PREVENTION

COMMITTEE FOR HUMAN MEDICINAL PRODUCTS (CHMP) DRAFT GUIDELINE ON THE EVALUATION OF MEDICINAL PRODUCTS FOR CARDIOVASCULAR DISEASE PREVENTION European Medicines Agency London, 19 July 2007 Doc. Ref. EMEA/CHMP/EWP/311890/2007 COMMITTEE FOR HUMAN MEDICINAL PRODUCTS (CHMP) DRAFT GUIDELINE ON THE EVALUATION OF MEDICINAL PRODUCTS FOR CARDIOVASCULAR

More information

2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk

2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation, American Society for Preventive Cardiology, American

More information

Empagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk

Empagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk Empagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk Silvio E Inzucchi, Christoph Wanner, John M Lachin, David Fitchett, Stefan Hantel, Michaela

More information

Statin Therapy An Update on Adverse Effects. Aaron Weisbord, MD, FACC South County Cardiology Division

Statin Therapy An Update on Adverse Effects. Aaron Weisbord, MD, FACC South County Cardiology Division Statin Therapy An Update on Adverse Effects Aaron Weisbord, MD, FACC South County Cardiology Division Introduction Statin use has been associated with many potential side effects. Statin intolerance rates

More information

Disclosures. Objective. Educational Need/Practice Gap. Lecture Content. CVD is an Inflammatory Disorder

Disclosures. Objective. Educational Need/Practice Gap. Lecture Content. CVD is an Inflammatory Disorder Findings from large clinical trials of anti-inflammatory drugs and vitamins to prevent heart attack and stroke Robert C. Block, MD, MPH, FACP, FNLA Associate Professor Dept of Public Health Sciences; Cardiology

More information

MANAGEMENT of HYPERTENSION. R. Michael Culpepper, M.D. University of South Alabama

MANAGEMENT of HYPERTENSION. R. Michael Culpepper, M.D. University of South Alabama MANAGEMENT of HYPERTENSION R. Michael Culpepper, M.D. University of South Alabama DISCLOSURE Any Drug or Product Mentioned in this Discussion is Purely Illustrative and not a Commercial Endorsement All

More information

Chapter 1: CKD in the General Population

Chapter 1: CKD in the General Population Almost half of individuals with CKD also have diabetes and/or self-reported CVD. Overall prevalence of CKD in the general population is approximately 14, which closely mirrors the prevalence of individuals

More information

Cost impact and percentage of Native American patients with Type 2 DM and Cardiovascular Disease with the ATP III recommendation of an LDL <70.

Cost impact and percentage of Native American patients with Type 2 DM and Cardiovascular Disease with the ATP III recommendation of an LDL <70. Cost impact and percentage of Native American patients with Type 2 DM and Cardiovascular Disease with the ATP III recommendation of an LDL

More information

Will The Coronary Calcium Score Affect the Decision To Treat With Statins?

Will The Coronary Calcium Score Affect the Decision To Treat With Statins? Will The Coronary Calcium Score Affect the Decision To Treat With Statins? Amresh Raina M.D. Division of Cardiology University of Pennsylvania Disclosures No financial relationships relevant to this presentation

More information

New Cholesterol Guidelines ACC/AHA 2013

New Cholesterol Guidelines ACC/AHA 2013 New Cholesterol Guidelines ACC/AHA 2013 ObamaCare Version Kelly W. Jones, Pharm.D., BCPS McLeod Family Medicine Center Disclaimer I have no conflict of interest relating in the material covered today.

More information

COGNITIVE IMPAIRMENT

COGNITIVE IMPAIRMENT PREVENTING DEMENTIA AND COGNITIVE IMPAIRMENT VASCULAR FACTORS, DIABETES, AND OBESITY: OBSERVATIONAL EVIDENCE Rebecca Gottesman, MD PhD Associate Professor of Neurology and Epidemiology Johns Hopkins University

More information

Women and Heart Disease. Susan Thompson Hingle, M.D

Women and Heart Disease. Susan Thompson Hingle, M.D Women and Heart Disease Susan Thompson Hingle, M.D Causes of Death in Women Heart Disease Cerebrovascular Disease Lung Cancer COPD Pneumonia/Flu Breast Cancer Accidents Diabetes Ovarian Cancer 370/1000

More information

Statins and Risk for Diabetes Mellitus. Background

Statins and Risk for Diabetes Mellitus. Background Statins and Risk for Diabetes Mellitus Kevin C. Maki, PhD, FNLA Midwest Center for Metabolic & Cardiovascular Research and DePaul University, Chicago, IL 1 Background In 2012 the US Food and Drug Administration

More information

Cholesterol Treatment Trialists (CTT) Collaboration. Slide deck

Cholesterol Treatment Trialists (CTT) Collaboration. Slide deck Cholesterol Treatment Trialists (CTT) Collaboration Slide deck CTT Collaboration: Background* History: Founded in 1993 (prior to publication of 4S trial in 1994) Original protocol published in 1995 Trial

More information